Apellis Pharmaceuticals, Inc.
1 appearance
Latest appearance 2021-06-30
Federico Grossi
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Federico Grossi
Apellis Pharmaceuticals, Inc. reported in an 8-K filed January 5, 2023 that Federico Grossi resigned as Chief Medical Officer, effective January 3, 2023. The proxy statement of Apellis Pharmaceuticals, Inc. reports total compensation of $2,616,139 for Federico Grossi in fiscal 2021, including a base salary of $436,539. Federico Grossi has spoken on 1 earnings call across 1 company, most recently for Apellis Pharmaceuticals, Inc. on June 30, 2021.
“Dr. Grossi will cease to serve as Chief Medical Officer effective as of January 3, 2023 and will continue at the Company until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Apellis Pharmaceuticals, Inc.
Source not stated
Start not stated–2023-01-03
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Apellis Pharmaceuticals, Inc. | M.D., Ph.D. Chief Medical Officer | $436,539 | $2,616,139 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
-
-
Earnings call
Apellis Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Apellis Pharmaceuticals, Inc.